- P-ISSN 1225-0163
- E-ISSN 2288-8985
본 연구는 혈청 중 두타스테라이드의 확인과 정량을 위하여 LC-ESI-MS/MS를 이용한 신뢰성 있는 분석법을 개발하고, 분석방법의 타당도를 검증하고자 수행하였다. 내부표준물질인 베클로메타손을 첨가한 혈청을 methyl tert-butyl ether (MTBE)를 사용하여 액체상추출법(liquid-liquid extraction, LLE)으로 추출하였다. LC-MS/MS의 양이온 모드에서 MRM(multiple reaction monitoring)방법으로 확인한 두타스테라이드와 베클로메타손의 mass transition은 각각 m/z 529.6→461.5, m/z 409.3→391.2 이었으며, 머무름 시간은 각각 6.45분, 5.46분이었다. 검량선은 0.5~30.0 ng/mL의 농도 범위에서 R2=0.9999의 높은 직선성을 나타내었으며, 정량한계와 회수율은 각각 0.5 ng/mL와 66~72% 이었다. 일내에 대한 정밀도는 3.5~5.5%, 정확도는 85.7~89.9% 범위이었으며, 연속 3일간 수행한 일간 정밀도는 4.2~5.8%, 정확도는 90.8~95.8% 이었다.
The determination and confirmation of dutasteride in human serum was performed by a liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI/MS/MS). Beclomethasone as an internal standard (I.S.) was added to the serum and the mixed sample was pretreated by liquid-liquid extraction (LLE) with methyl tert-butyl ether (MTBE). The mass transitions of dutasteride and I.S. monitored in multiple reaction monitoring (MRM) were m/z 529.6→461.5 and m/z 409.3→391.2, respectively, and the retention times were 6.45 and 5.46min, respectively. The calibration curve was linear in the concentration range of 0.5~30.0 ng/mL (R2= 0.9999) and the limit of quantitation (LOQ) was found to be 0.5 ng/mL. The recovery of dutasteride was shown to be 66~72%. The intra-day assay precision and accuracy were in the range 3.5~5.5% and 85.7~89.9%, respectively, and the interday assay precision and accuracy were in the range 4.2~5.8% and 90.8~95.8%, respectively
1. C. G. Roehrborn, P. Boyle, J. C. Nickel, K. Hoefner and G. Andriole, Urol., 60, 434-441 (2002).
2. H. C. Evans and K. L. Goa, Drugs Aging., 20(12), 905-916 (2003).
3. K. K. Gaines, Urol. Nurs., 23(3), 218-220 (2003).
4. G. L. Andriole and R. Kirby, Eur. Urol., 44, 82-88(2003).
5. F. Debruyne, J. Barkin, P. van Erps, M. Reis, T. L. J. Tammela and C. Roehrborn, Eur. Urol., 46(4), 488-495(2004).
6. R. V. Clark, D. J. Hermann, G. R. Cunningham, T. H. Wilson, B. B. Morrill and S. Hobbs, J. Clin. Endocrinol Metab., 89(5), 2179-1284 (2004).
7. E. A. Olsen, M. Hordinskym, D. Whiting, D. Stough, S. Hobbs, M. L. Ellis, T. Wilson and R. S. Rittmaster, J. AM ACAD DERMATOL., 55(6), 1014-1026 (2006).
8. M. Marberger, C. G. Roehrborn, L. S. Marks, T. Wilson and R. S. Rittmaster, J. Clin. Endocrinol. Metab., 91(4), 1323-1328 (2006).
9. C. G. Roehrborn, P. Siami, J. Barkin, R. Damião, K. Major-Walker, B. Morrill and F. Montorsi, CombAT Study Group, J. Urol., 179(2), 616-621 (2008).
10. J. C. Nickel, Urol., 6(9), S31-39 (2004).
11. N. Makridakis and J. K. V. Reichardt, J. Mol. Endocrinol., 34, 617-623 (2005).
12. J. K. Amory, C. Wang, R. S. Swerdloff, B. D. Anawalt, A. M. Matsumoto, W. J. Bremner, S. E. Walker, L. J. Haberer and R. V. Clark, J. Clin. Endocrinol. Metab., 92(5), 1659-1665 (2007).
13. C. L. Foley, S. R. Bott, I. S. Shergill and R. S. Kirby, Drugs. Today., 40(3), 213 (2004).
14. A. M. Traish, J. Hassani, A. T. Guay, M. Zitzmann and M. L. Hansen, J. Sexual. Medicine., 8(3), 872-884 (2011).
15. Blood Guidances, Food and Drug Administration, USA, 2011.
16. Blood Regulation Law, Ministry of Health and Welfare, Korea, 2011.
17. N. V. S. Ramakrishna, K. N. Vishwottam, S. Puran, M. Koteshwara, S. Manoj and M. Santosh, J. Chromatogr B., 809(1), 117-124 (2004).
18. S. Agarwal, K. V. Gowda, A. K. Sarkar, D. Ghosh, U. Bhaumik, T. K. Chattarai and T. K. Pal, Chromatographia., 67, 893-903 (2008).
19. N. A. Gomes, A. Pudage, S. S. Joshi, V. V. Vaidya, S. A. Parekh and A. V. Tamhankar, Chromatographia., 69, 9-18 (2009).
20. Bioanalytical Method Validation, National Institute of Food and Drug Safety Evaluation, Korea, 2009.
21. Guidance for Industry, Bioanalytical Method Validation, Food and Drug Administration, USA, 2001.